New antibody shows promise in slowing early myeloma

NCT ID NCT01222286

Completed Disease control Sponsor: Innate Pharma Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tested an antibody drug called IPH2101 in 30 people with smoldering multiple myeloma, an early form of bone marrow cancer. The drug aims to boost the immune system to attack cancer cells. Researchers measured how well it controlled the disease and checked for side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: IPH2101 (an antibody that helps immune cells attack cancer)
What this could lead to: If it works, this could point toward a treatment that delays or prevents smoldering multiple myeloma from becoming active cancer.
What could go wrong: This is a small, early-phase trial with only 30 participants, so results may not apply broadly. The drug may not shrink tumors or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMOLDERING MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Smoldering Multiple Myeloma smoldering plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMOLDERING MULTIPLE MYELOMA

Contacts and locations

Locations

Dana-Farber Cancer Institute

Boston, Massachusetts, 02115, United States
Hospital of the University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
Mount Sinai School of Medicine

New York, New York, 10029, United States
Ohio State University

Columbus, Ohio, 43210, United States
Sarah Cannon Research Institute

Nashville, Tennessee, 37203, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.